Association between <em>TP53</em> gene Arg72Pro polymorphism and Wilms&rsquo; tumor risk in a Chinese population

Abstract

Wilms’ tumor is one of the most prevalent pediatric malignancies, ranking fourth in childhood cancer worldwide. TP53 is a critical tumor suppressor gene, which encodes a 53 kDa protein, p53. The p53 functions to protect against cancer by regulating cell cycle and apoptosis and maintaining DNA integrity. TP53 gene is highly polymorphic. Several TP53 gene polymorphisms have been considered to be associated with cancer risk. Of them, a nonsynonymous polymorphism, Arg72Pro (rs1042522 C>G), has been most extensively studied for the association with cancer risk; however, few studies have investigated its effect on Wilms’ tumor. Because of the central role of p53 in cell cycle control, the TP53 gene Arg72Pro polymorphism is also a good potential candidate predisposition locus for this pediatric cancer. We genotyped this polymorphism in 145 patients and 531 cancer-free controls recruited from Chinese children by Taqman methodology. Overall, our result suggested a lack of association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor. In the stratified analysis, we found that carriers of CG/GG genotypes had a significantly increased Wilms’ tumor risk in children not older than 18 months (adjusted odds ratio =2.04, 95% confidence interval =1.003–4.13, P=0.049) compared with CC genotype carriers. Our study indicated that the TP53 gene Arg72Pro polymorphism may have a weak, age-related effect on Wilms’ tumor risk in Chinese children. These findings need further validations in other populations with larger sample size.

Association between NER Pathway Gene Polymorphisms and Wilms Tumor Risk

“…The 145 cases in the study were individuals newly diagnosed with neuroblastoma from the Guangzhou Women and Children’s Medical Center 19, 20, 21, 22, 23, 35. All tumors were histopathologically confirmed.…”

The association of miR34b/c and TP53 gene polymorphisms with Wilms tumor risk in Chinese children

“…A study by Liu et al [39] revealed that the effect of TP53 rs1402522 polymorphism on Wilms tumor risk is very weak, which is consistent with our result. Another study conducted by Fu et al [40] also showed no significant association between TP53 rs1402522 polymorphism and Wilms tumor risk, and they found that CG/GG genotypes carriers significantly increased Wilms tumor risk in children younger than 18 months of age, compared with CC genotype carriers. Moreover, it is reported that TP53 rs1042522 may not confer susceptibility to cancers, such as neuroblastoma [41], retinoblastoma [42].…”

Associations between LMO1 gene polymorphisms and Wilms' tumor susceptibility

“…For the present study, 145 patients with newly diagnosed and histologically confirmed Wilms’ tumor were recruited from the Department of Pediatric Urology, Guangzhou Women and Children's Medical Center between March 2001 and June 2016, while 531 cancer-free children undergoing routine physical examinations in the same hospital were randomly selected as controls. All the subjects were genetically unrelated ethnic Han Chinese from South China [ 24 , 25 , 43 ]. The response rate was approximately 90% for Wilms’ tumor patients and 95% for cancer-free controls.…”

“…The Wilms’ tumor gene was the first identified suppressor of Wilms’ tumor development [ 19 ]. Thereafter, several susceptibility genes were found predispose individuals to Wilms’ tumor, such as FWT1 [ 20 ], FWT2 [ 21 ], BRCA2 [ 22 ], TP53 [ 23 , 24 ], BARD1 [ 25 ] and CTR9 [ 26 ]. The LIM domain only 1 ( LMO1 ) gene is located at 11p15, and encodes a cysteine-rich two-LIM-domain transcriptional regulator.…”